Abstract
Objective
Multiple myeloma is characterized by an accumulation of plasma cells in bone marrow. Despite many therapeutic regimens introduced recently, the prognosis for patients suffering from treatment-resistant or relapsing multiple myeloma is still very poor. Thus, there is an urgent medical need for novel innovative drugs. Thalidomide is successfully used in resistant or relapsing myeloma patients, being reported to induce apoptosis or G1 growth arrest of myeloma cells and to regulate microvessel density and cytokine secretion. Lovastatin, largely used for the treatment of hypercholesterolemia, is another promising drug in multiple myeloma. High doses of lovastatin have been shown to have antiproliferative effect by inhibition of malignant cell proliferation and inducing programmed cell death.
Methods
In this study, we tried to assess whether thalidomide and lovastatin had a combined effect on apoptosis of myeloma cells. We analyzed apoptosis induced by mixture of these two drugs in short-term cell culture of myeloma plasmocytes. To assess apoptosis, we used Annexin V and propidium iodide binding. We also examined the regulation of BCL-2 and BAX protein expression in the population of CD138+ plasmocytes. The cells were analyzed with the use of flow cytometry technique. The experiments were done before and after 72 h of cell culture.
Results
We detected a higher rate of apoptosis induced by lovastatin and thalidomide mixture in comparison to apoptosis induced by lovastatin or thalidomide alone. In most patients, the BCL-2/BAX ratio was lower in cell cultures supplemented with mixture of lovastatin and thalidomide in comparison with cell cultures supplemented with lovastatin or thalidomide alone.
Conclusion
Based on our research we conclude that the mixture of lovastatin and thalidomide may increase the rate of multiple myeloma cells apoptosis in comparison to the single drug and the precise mechanism of this effect should be approved by further research.
This is a preview of subscription content, log in via an institution to check access.
References
Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR (1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5:2223–2229
Calabrese L, Fleischer AB (2000) Thalidomide: current and potential clinical applications. Am J Med 108:487–495
Dmoszynska A, Rolinski J, Bojarska-Junak A, Manko J, Jawniak D, Walter-Croneck A, Soroka-Wojtaszko M (2001) Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients. Pol J Pharmacol 53:709–713
Dmoszyńska A, Podhorecka M, Roliński J, Soroka-Wojtaszko M (2004) Influence of lovastatin on BCL-2 and BAX expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells. Pol J Pharmacol 56:485–489
Feleszko W, Młynarczyk J, Balkiewiec-Iskra EZ, Cajak A, Switaj T, Stokłosa T, Giermasz A, Jakobisiak M (2000) Lovastatin potentiates antitumor activity and atenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6:2044–2052
Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I (2000) Therapy with thalidomide in refractory multiple myeloma patients: the revival of an old drug. Br J Haematol 108:391–393
Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J (1995) Interleukion 6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248–255
Lishner M, Bar-Sef A, Elis A, Fabian I (2001) Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 49:319–324
Marriot JB, Muller G, Dalgleish AG (1999) Thalidomide as an emerging immunotherapeutic agent. Immunol Today 20:538–554
Moncada B, Baranda ML, Gonzales-Amaro R, Urbina R, Loredo CE (1985) Thalidomide - effect on T cell subsets is a possible mechanisms of action. Int J Lepr Other Mycobact Dis 53:201–205
Reed JC (1998) BCL-2 family proteins. Oncogene 17:3225–3236
Sampaio EP, Sarno NN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173:699–703
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571
Spets H, Stromberg T, Georgii Hemminng P, Siljason J, Nilsson K, Jernberg-Wiklund H (2002) Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells : regulation during interleukin-6 -induced growth and survival. Eur J Haematol 69:76–89
Thibault A, Samid D, Tompkims AC (1996) Phase I study of lovastatin an inhibitor of the mevalonate pathway in patients with cancer. Clin Cancer Res 2:483–491
Van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362–1371
Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105:739–748
Acknowledgement
This study was supported by the grant No. 3PO5B04623 from the State Committee for Scientific Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dmoszynska, A., Podhorecka, M., Klimek, P. et al. Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. Eur J Clin Pharmacol 62, 325–329 (2006). https://doi.org/10.1007/s00228-006-0106-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-006-0106-2